Home › Funds › Patient Square Capital LP › RCUS

Patient Square Capital LP position in RCUS

ARCUS BIOSCIENCES INC · Health Care

Patient Square Capital LP reported holding 410,000 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$10.6M, representing 1.69% of its reported portfolio and ranking #15 among its reported holdings. Patient Square Capital LP has disclosed RCUS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)410.00K sh
Reported value held$10.59M
Portfolio Weight1.69%
First reportedQ4 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Patient Square Capital LP's RCUS position evolved

Patient Square Capital LP first disclosed a stake in RCUS in Q4 2025 at 170,000 shares (US$4.1M). The position peaked in Q2 2026 at 355,800 shares, worth US$11.0M. Across 4 filings, Patient Square Capital LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 410,000 shares valued at US$10.6M — an increase of 54,200 shares quarter over quarter.. Notable position changes include a 82% increase in Q2 2026 (shares fell 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 170.00K $4.05M New
Q1 2026 195.00K $4.21M Add
Q2 2026 355.80K $10.97M Add
Q3 2026 410.00K $10.59M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RCUS and 13F data

RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 47 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$811.7M), MONTANOVA CAPITAL, LLC (US$147.3M), Siren, L.L.C. (US$62.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RCUS

All RCUS fund holders →

FAQ

How long has Patient Square Capital LP held RCUS?

Patient Square Capital LP has disclosed RCUS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Patient Square Capital LP's current position in RCUS?

As of Q3 2026, Patient Square Capital LP holds 410.00K shares of RCUS (ARCUS BIOSCIENCES INC), valued at $10.59M, representing 1.69% of its reported portfolio and ranking #15.

Has Patient Square Capital LP been buying or selling RCUS?

In the latest 13F filing (Q3 2026), Patient Square Capital LP increased its position in RCUS. The position peaked in Q2 2026 at 355.80K shares.

Which other funds hold RCUS?

Other major institutional holders of RCUS include GILEAD SCIENCES, INC., MONTANOVA CAPITAL, LLC, Siren, L.L.C., among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.